{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=62546", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=62546", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=62546&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=62546&_page=0", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=62546", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=62546", "items" : [{"_about" : "http://data.parliament.uk/resources/1216164", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1216164/answer", "answerText" : {"_value" : "

The Government is in continual dialogue with the insurance sector to understand and influence its contribution to handling this unprecedented situation.<\/p>

<\/p>

The Financial Conduct Authority (FCA) rules require insurers to handle claims fairly and promptly; provide reasonable guidance to help a policyholder make a claim; not reject a claim unreasonably; and settle claims promptly once settlement terms are agreed. In addition, the FCA has said that, in light of COVID-19, insurers must consider very carefully the needs of their customers and show flexibility in their treatment of them. The Government is working closely with the FCA to ensure that the rules are being upheld during this crisis and fully supports the regulator in its role.<\/p>

<\/p>

The FCA have also issued guidance for travel insurance customers, which can be found on their website.<\/p>

We have discussed with insurers the importance of insurance cover for Covid-19 in restoring consumer confidence to travel again. Firms assure us that they will look to offer cover again where and when they can. They are monitoring announcements by Government and reviewing their position as the situation evolves. We will continue to monitor this situation closely.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4051", "label" : {"_value" : "Biography information for John Glen"} } , "answeringMemberConstituency" : {"_value" : "Salisbury"} , "answeringMemberPrinted" : {"_value" : "John Glen"} , "dateOfAnswer" : {"_value" : "2020-06-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-06-29T16:08:11.573Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "Treasury"} , "date" : {"_value" : "2020-06-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Travel: Insurance Companies"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Chancellor of the Exchequer, what steps he is taking to ensure that travel insurance companies are (a) communicating clearly to their consumers and (b) treating them fairly.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4572", "label" : {"_value" : "Biography information for Chris Elmore"} } , "tablingMemberConstituency" : {"_value" : "Ogmore"} , "tablingMemberPrinted" : [{"_value" : "Chris Elmore"} ], "uin" : "62546"} , {"_about" : "http://data.parliament.uk/resources/682334", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/682334/answer", "answerText" : {"_value" : "

The Government has been at the forefront of action to address antimicrobial resistance (AMR). The risk of infection from multidrug-resistant bacteria (or \u201csuperbugs\u201d) is not confined to cancer treatment but has implications for a wide range of medical treatments and interventions, including routine surgery.<\/p>

<\/p>

The UK Five Year Antimicrobial Resistance Strategy, published in 2013, set out an ambitious programme to slow the development and spread of AMR taking a \u201cOne-Health\u201d approach spanning people, animals, agriculture and the wider environment.<\/p>

<\/p>

The Strategy seeks to prevent infection, protect the antibiotics that we have and promote the development of new drugs and alternative treatments. Progress on these actions has been reported in the Second Annual Progress report available at:<\/p>

https://www.gov.uk/government/publications/progress-report-on-the-uk-5-year-amr-strategy-2015<\/a><\/p>

<\/p>

In September 2016, the Government published its response to the Independent Review on AMR, led by Lord O\u2019Neill. This is available at:<\/p>

https://www.gov.uk/government/publications/government-response-the-review-on-antimicrobial-resistance<\/a><\/p>

<\/p>

The response sets out further ambitions to address the challenges of antimicrobial resistance, including the following domestic ambitions:<\/p>

- A reduction in healthcare associated Gram-negative bloodstream infections in England by 50% by 2020; and<\/p>

- A reduction in inappropriate antibiotic prescribing by 50%, with the aim of being a world leader in reducing prescribing by 2020.<\/p>

<\/p>

Internationally, the UK continues to lead in tackling AMR through globally co-ordinated and sustainably funded action. In September 2016, the Government\u2019s leadership helped secure a UN declaration on AMR and a commitment from the G20 to look at solutions to the market failure on the development of new antimicrobials.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2017-02-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-02-08T17:39:54.04Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-01-31", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what steps his Department is taking to ensure that superbugs do not make cancer untreatable.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "62546"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }